docetaxel anhydrous has been researched along with curdione in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (curdione) | Trials (curdione) | Recent Studies (post-2010) (curdione) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 40 | 0 | 30 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, J; Wang, C; Wu, Z | 1 |
1 other study(ies) available for docetaxel anhydrous and curdione
| Article | Year |
|---|---|
Combinative treatment of Curdione and docetaxel triggers reactive oxygen species (ROS)-mediated intrinsic apoptosis of triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sesquiterpenes, Germacrane; Signal Transduction; Triple Negative Breast Neoplasms | 2021 |